OSE Immunotherapeutics S.A.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
OSE Immunotherapeutics S.A. - Asset Resilience Ratio
OSE Immunotherapeutics S.A. (0RAD) has an Asset Resilience Ratio of 3.12% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2018)
This chart shows how OSE Immunotherapeutics S.A.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down OSE Immunotherapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.96 Million | 3.12% |
| Total Liquid Assets | €2.96 Million | 3.12% |
Asset Resilience Insights
- Limited Liquidity: OSE Immunotherapeutics S.A. maintains only 3.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
OSE Immunotherapeutics S.A. Industry Peers by Asset Resilience Ratio
Compare OSE Immunotherapeutics S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for OSE Immunotherapeutics S.A. (2016–2018)
The table below shows the annual Asset Resilience Ratio data for OSE Immunotherapeutics S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 3.72% | €2.86 Million | €76.90 Million | -0.01pp |
| 2017-12-31 | 3.73% | €2.88 Million | €77.35 Million | +0.51pp |
| 2016-12-31 | 3.22% | €2.88 Million | €89.55 Million | -- |